Bisphosphonate therapy in children with secondary osteoporosis

Hormone Research in Paediatrics

Volumn 76, Issue SUPPL. 1, 2011, Pages 24-27

  Papapoulos, Socrates E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bisphosphonates; Children; Fractures; Secondary osteoporosis

Indexed keywords

ALENDRONIC ACID; ANTICONVULSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; CYCLOSPORIN; GLUCOCORTICOID; GONADORELIN AGONIST; METHOTREXATE; PAMIDRONIC ACID; TECHNETIUM; THYROXINE; VITAMIN D;

AMENORRHEA; ARTHRITIS; BONE DENSITY; BONE FRAGILITY; BONE GROWTH; BONE MASS; BONE METABOLISM; BONE REMODELING; BONE SCINTISCANNING; BONE STRENGTH; CELL VIABILITY; CEREBRAL PALSY; CHILDHOOD DISEASE; CONFERENCE PAPER; CONNECTIVE TISSUE; CONTROLLED CLINICAL TRIAL (TOPIC); CUSHING SYNDROME; CYSTIC FIBROSIS; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG EXCRETION; DRUG HALF LIFE; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; DUCHENNE MUSCULAR DYSTROPHY; ENTERITIS; FRACTURE HEALING; GALACTOSEMIA; GAUCHER DISEASE; GLYCOGEN STORAGE DISEASE; GROWTH PLATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMOBILIZATION; JUVENILE OSTEOPOROSIS; KIDNEY FAILURE; LEUKEMIA; LONG BONE; MARFAN SYNDROME; MOBILIZATION; NEOPLASM; ORGAN TRANSPLANTATION; OSTEOCYTE; OSTEOGENESIS IMPERFECTA; OSTEOLYSIS; OSTEOPOROSIS; PLACENTA; PRIMARY BILIARY CIRRHOSIS; PRIMARY OSTEOPOROSIS; PRIORITY JOURNAL; PUBERTY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATIC DISEASE; SAMPLE SIZE; SECONDARY OSTEOPOROSIS; SIDE EFFECT; SKELETON; SPINAL CORD INJURY; THALASSEMIA; URINARY EXCRETION; VERTEBRA FRACTURE;

BONE DENSITY; BONE DEVELOPMENT; BONE DISEASES; CHILD; DIPHOSPHONATES; FRACTURES, BONE; HUMANS; OSTEOPOROSIS;

EID: 79960706002     PISSN: 16632818     EISSN: 16632826     Source Type: Journal    
DOI: 10.1159/000329151     Document Type: Conference Paper

References (21)

1. Consensus development conference on osteoporosis. Hong Kong, April 1-2, 1993. Am J Med 1993; 95: 1S-78S.
2. Bianchi ML: Osteoporosis in children and adolescents. Bone 2007; 41: 486-495. (Pubitemid 47386052)
3. Bachrach LK, Ward LM: Clinical review: bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab 2009; 94: 400-409.
4. Baim S, Leonard MB, Bianchi ML, Hans DB, Kalkwarf HJ, Langman CB, Rauch F: Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD pediatric position development conference. J Clin Densitom 2008; 11: 6-21. (Pubitemid 351602184)
5. Leet AI, Mesfin A, Pichard C, Launay F, Brintzenhofeszoc K, Levey EB, Sponseller P: Fractures in children with cerebral palsy. J Pediatr Orthop 2006; 26: 624-627. (Pubitemid 44315843)
6. Helenius I, Remes V, Salminen S, Valta H, Mäkitie O, Holmberg C, Palmu P, Tervahartiala P, Sarna S, Helenius M, Peltonen J, Jalanko H: Incidence and predictors of fractures in children after solid organ transplantation: a 5-year prospective, populationbased study. J Bone Miner Res 2006; 21: 380-387.
7. Burnham JM, Shults J, Weinstein R, Lewis JD, Leonard MB: Childhood onset arthritis is associated with an increased risk of fracture: a population based study using the General Practice Research Database. Ann Rheum Dis 2006; 65: 1074-1079. (Pubitemid 44133272)
8. van Staa TP, Cooper C, Leufkens HGM, Bishop N: Children and the risk of fractures caused by oral corticosteroids. J Bone Miner Res 2003; 18: 913-918. (Pubitemid 37294976)
9. Papapoulos SE: Bisphosphonates for postmenopausal osteoporosis; in Rosen CJ (ed): Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Washington, American Society for Bone and Mineral Research, 2008, pp 237-241.
10. Papapoulos SE: Bisphosphonates: how do they work? Best Pract Res Clin Endocrinol Metab 2008; 22: 831-847.
11. Rauch F, Travers R, Munns C, Glorieux FH: Sclerotic metaphyseal lines in a child treated with pamidronate: histomorphometric analysis. J Bone Miner Res 2004; 19: 1191-1193. (Pubitemid 41110572)
12. Rauch F, Cornibert S, Cheung M, Glorieux FH: Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. Bone 2007; 40: 821-827. (Pubitemid 46386546)
13. Ward KA, Adams JE, Freemont TJ, Mughal MZ: Can bisphosphonate treatment be stopped in a growing child with skeletal fragility? Osteoporos Int 2007; 18: 1137-1140. (Pubitemid 47019997)
14. Cremers SCLM, Pillai GC, Papapoulos SE: Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 2005; 44: 551-570. (Pubitemid 40994085)
15. Papapoulos SE, Cremers SC: Prolonged bisphosphonate release after treatment in children. N Engl J Med 2007; 356: 1075-1076. (Pubitemid 46376827)
16. Levy S, Fayez I, Taguchi N, Han JY, Aiello J, Matsui D, Moretti M, Koren G, Ito S: Pregnancy outcome following in utero exposure to bisphosphonates. Bone 2009; 44: 428-430.
17. van Persijn van Meerten EL, Kroon HM, Papapoulos SE: Epi-and metaphyseal changes in children caused by bisphosphonates. Radiology 1992; 184: 249-254.
18. Brumsen C, Hamdy NAT, Papapoulos SE: Long-term effects of bisphosphonates on the growing skeleton; studies of young patients with severe osteoporosis. Medicine 1997; 76: 266-283.
19. Rauch F, Glorieux FH: Osteogenesis imperfecta. Lancet 2004; 363: 1377-1385. (Pubitemid 38529880)
20. Albright F, Reifenstein AB Jr: The Parathyroid Glands and Metabolic Bone Disease. Baltimore, Williams and Wilkins, 1948.
21. Ward L, Tricco AC, Phuong P, Cranney A, Barrowman N, Gaboury I, Rauch F, Tugwell P, Moher D: Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst Rev 2007;CD005324.